NEW YORK – Swedish genetic test developer Devyser announced Wednesday it has received CE marking for its next-generation sequencing-based hereditary breast and ovarian cancer assay.
The targeted sequencing test analyzes 12 genes and uses a proprietary amplification-based library preparation.